Abstract This study compared costs and clinical outcomes of invasive versus non-invasive diagnostic evaluations for patients with suspected in-stent restenosis (ISR) after percutaneous coronary intervention. We developed a decision model to compare 2 year diagnosis-related costs for patients who presented with suspected ISR and were evaluated by: (1) invasive coronary angiography (ICA); (2) non-invasive stress testing strategy of myocardial perfusion imaging (MPI) with referral to ICA based on MPI; (3) coronary CT angiography-based testing strategy with referral to ICA based on CCTA. Costs were modeled from the payer's perspective using 2014 Medicare rates. 56 % of patients underwent follow-up diagnostic testing over 2 years. Compared to ICA, MPI (98.6 %) and CCTA (98.1 %) exhibited lower rates of correct diagnoses. Noninvasive strategies were associated with reduced referrals to ICA and costs compared to an ICA-based strategy, with diagnostic costs lower for CCTA than MPI. Overall 2-year costs were highest for ICA for both metallic as well as BVS stents ($1656 and $1656, respectively) when compared to MPI ($1444 and $1411) and CCTA. CCTA costs differed based upon stent size and type, and were highest for metallic stents [3.0 mm followed by metallic stents \3.0 mm, BVS \ 3.0 mm and BVS [ 3.0 mm ($1466 vs. $1242 vs. $855 vs. $490, respectively). MPI for suspected ISR results in lower costs and rates of complications than invasive strategies using ICA while maintaining high diagnostic performance. Depending upon stent size and type, CCTA results in lower costs than MPI.
Introduction
In the United States each year, approximately 954,000 percutaneous coronary interventions (PCI) are performed [1] . While the introduction of bare metal stents (BMS) and drug eluting metallic stents (DES) has dramatically reduced the incidence of restenosis rates over primary angioplasty alone, current generation drug eluting stents (DES) and bare metal stents (BMS) are nevertheless affected by in-stent restenosis (ISR) rates of up to 5 and 30 % within the first year following implantation, respectively [2, 3] .
The diagnostic approach to patients with suspected ISR has been difficult [4] . While invasive coronary angiography (ICA) has been considered the ''gold standard'' test for evaluation of patients with suspected ISR, it is nevertheless costly and carries the risk of complications. Historically, many individuals with suspected ISR have undergone diagnostic evaluation by stress testing-most commonly with myocardial perfusion imaging (MPI) by single photon emission computed tomography (SPECT)-with variable efficacy, and the final determination of stent patency often requires invasive evaluation by coronary angiography (ICA) [5] .
In recent years, coronary CT angiography (CCTA) has emerged as a potential non-invasive alternative to ICA, and has demonstrated high diagnostic performance for the detection and exclusion of high-grade anatomic stenosis in native coronary arteries [6] [7] [8] . Yet CCTA exhibits a lower diagnostic performance for evaluation of intracoronary stents that is largely ascribed to partial volume and beam hardening CT artifacts [9, 10] . Importantly, diagnostic performance of CCTA is dependent upon stent size and type, with higher accuracy for larger over small diameters, and for polymerbased bioresorbable scaffolds (BVS) over metallic stents.
To date, the downstream costs and clinical outcomes associated with invasive versus non-invasive evaluation of patients with suspected ISR has not been evaluated. We thus developed a contemporary decision analytic model to estimate the efficacy of evaluation of patients with suspected ISR using ICA, MPI or CCTA.
Methods
We assessed the costs of three strategies for diagnostic evaluation of patients with symptomatic angina with suspected ISR after PCI. These strategies were as follows: (a) an invasive strategy of direct referral to ICA for all patients; (b) a stress MPI strategy of SPECT, with selective referral to ICA after abnormal or equivocal SPECT; (c) a CCTA-based strategy, with selective referral to ICA after abnormal or equivocal CCTA (Fig. 1 ). Costs were assigned from the perspective of the healthcare payer.
Decision analytic model
We developed a decision analytic model over a 2-year time horizon to evaluate diagnostic work-up strategies, in accordance to the expected length of the episode of care.
Test sensitivity, specificity, rates of equivocal test results, and disease prevalence were used to classify patients undergoing ICA, MPI and CCTA as patients with truepositive, false-positive, true-negative, false-negative or equivocal findings for significant ISR. All patients with positive or equivocal findings by CCTA were assumed to be referred to ICA, and ICA was assumed to have perfect sensitivity and specificity.
To compare degrees of abnormality by ICA, MPI and CCTA, we considered two categories relating to the extent and severity of abnormality by each method. For ICA and CCTA, an abnormal test requiring potential intervention was defined as 50 % of greater stenosis in the PCI-related artery. For MPI, any stress-induced perfusion defect was considered to be abnormal and was classified as requiring potentially actionable intervention.
To account for the differential diagnostic performance of CCTA for different stent size and type, we further stratified individuals by stent size and type, with (a) stent size as C3.0 versus\3.0 mm, and (b) stent type as metallic stent versus BVS (Fig. 2) . Metallic stents included both BMS and DES and were allocated in accordance with reported practice patterns. For the diagnostic performance of CCTA, patients with suspected ISR with metallic stents (BMS or DES) underwent evaluation by ICA for stents \3.0 mm and CCTA for stents C3.0 mm (in direct accordance with current American College of Cardiology Appropriate Use Criteria) [11] . Further, given the radio radiolucency of BVS but not metallic stents, all patients with suspected ISR who underwent PCI with BVS were evaluated by CCTA, irrespective of stent size [12] . Patients with negative MPI or CCTA were assumed to experience persistent angina symptoms and underwent ICA after continued presentation. 
Patient population
The modeled patient population included 1000 patients who underwent stent implantation for any reason, with approximately half of patients receiving \3 vs. C3.0 mm stents, in keeping with current clinical practice [13] [14] [15] . For metallic stents, the prevalence of use of DES and BMS was 74 and 26 %, respectively [16] .
Clinical presentation and disease prevalence
Rates of symptomatic angina with suspected ISR over the first year was estimated to be 28 %, while actual rates of ISR was 6.6 % for BMS and 3.0 % for DES and BVS [2, 3] . Restenosis rates for BVS were assumed to be equivalent to those of DES.
Test performance characteristics and risks of diagnostic testing
As the reference standard, ICA sensitivity and specificity was assumed to be 100 %. In contrast, the sensitivity and specificity of MPI was 87.0 and 87.0 %, with 16.6 % of studies considered equivocal [17] . CCTA sensitivity, specificity and equivocal rates for ISR for metallic stents was 50.2, 80.7 and 48.0 %, respectively, for metallic stents\3.0 mm; and 100.0, 48.5 and 46.0 %, respectively for metallic stents C3.0 mm. CCTA sensitivity, specificity and equivocal rates for BVS was assumed to be comparable to native coronary arteries at 70.0, 70.0 and 5.0 %, respectively for stents \3.0 mm; and 90.0, 96.0 and 5.0 %, respectively, for stents C3.0 mm [18] . Test complications were 0 % for both MPI and CCTA, and 2.0 % of the time for ICA [19, 20] .
Costs
Test performance costs were based upon current United States Medicare reimbursement rates, and were higher for ICA ($2854) than for MPI ($1222) and CCTA ($341) [21] . Costs of test complications for ICA were estimated to be $11,853 for the US, based upon previously published data and adjusted to 2013 US dollars using the Medical Care Component of the Consumer Price Index (CPI) [19, 22] . Costs were discounted at 3.0 % annually over the 2-year model time horizon.
Model outputs
Model outputs included the proportion of patients with suspected ISR (56 %) who were evaluated with ICA, MPI and CCTA, stress test, as well as overall diagnostic performance and total diagnostic costs per stented patient.
Results
The 2-year test rates and test outcomes per 1000 stented patients are listed in Table 1 by diagnostic strategy. In the ICA group, 100 % of patients with suspected ISR underwent ICA. In the MPI group, 45-48 % of evaluated patients underwent ICA regardless of stent type. In the CCTA group, 64 and 78 % of patients underwent ICA for metallic stents of \3.0 and C3.0 mm diameter, respectively; while 41 and 19 % of patients, respectively, underwent ICA for BVS stents \3.0 and C3.0 mm.
Correct diagnosis and downstream complication rates
Correct diagnoses were highest in the ICA cohort, with similar diagnostic performance of MPI and CCTA that ranged between 95 and 99 %. Test complications were lowest for MPI patients (0.9 %), followed by CCTA (1.0 %) and then ICA (2.0 %). Test complications were lower for CCTA when BVS was used. Overall, costs per stented patient were highest for an ICA strategy, followed by an MPI and then CCTA strategy (Fig. 2) . While 2-year ICA and MPI-based evaluation costs were generally similar based upon metallic versus BVS stent type, CCTA-based evaluation costs between $500 and $1500 depending on stent type and size.
Sensitivity analysis
We performed one-way sensitivity analyses varying key model parameters by 10 %. Key parameters included sensitivity, specificity and equivocal rates of test performance; stent-based angina rates and test costs ( Table 2 ). In this sensitivity analysis, costs were highest for ICA, followed by MPI and then CCTA. Additionally, the model appeared most sensitive to diagnostic test specificity and symptomatic angina rates.
Discussion
We developed a decision analytic model to compare costs and outcomes of invasive and non-invasive diagnostic strategies for evaluation of patients presenting with suspected ISR following PCI. We examined three algorithms that included ICA-, MPI-and CCTA-based strategies, and further examined the economic efficiencies when considering stent size and type. In this study, we observed high diagnostic performance of non-invasive strategies (ranging from 96 to 100 % correct diagnoses), with significant cost savings with both an MPI-and CCTA-based strategy. These non-invasive strategies resulted in a lower rate of referral to ICA than an invasive strategy with an associated reduction in the rate of complications. Importantly, the diagnostic performance and rates of complications of the CCTA-based approach was dependent upon both stent type, with overall costs lower for BVS stents. These findings remained consistent across the range of parameter values for test performance characteristics, angina rates, and test costs assessed in the sensitivity analyses.
To our knowledge, this study is the first decision analytic model to directly compare invasive versus non-invasive diagnostic strategies for evaluation of patients with suspected ISR, and suggests initial performance of MPI or CCTA as a potentially beneficial approach to evaluation of these patients. Given that ISR is an insidious rather than acute condition, a non-invasive evaluation is perhaps expected to be safer than an invasive evaluation for allcomers, and the findings of the present study support such a concept [23] . Although the cost savings appeared superior for a CCTA-based strategy over an MPI-based strategy, the CCTA-based strategy was associated with a small increase in rates of complications (1.0 vs. 0.9 %). Coupled with the high diagnostic performance of MPI observed in this study, patients with suspected ISR may be evaluated effectively by MPI, which is widely available and commonly practiced in the United States [24] [25] [26] .
Yet a ''one-size-fits-all'' strategy appears to be too simplistic when considering non-invasive imaging methods for ISR evaluation, as diagnostic costs, diagnostic performance and rates of complications differed according to stent size and type. We observed significant costs savings when CCTA was employed for evaluation of BVS (whether C3.0 or \3.0 mm) as compared to either CCTA for metallic stents or to MPI. These cost savings were driven by improved diagnostic test performance of CCTA in BVS patients due to enhanced visualization of the coronary lumen with non-metallic scaffolds. In this regard, CCTA for individuals with suspected ISR after BVS implantation may be more advantageous as an initial diagnostic strategy, and future prospective studies confirming this hypothesis now appear warranted [27, 28] .
Notably, we constructed the present decision analysis assuming uniformity of angina rates amongst individuals undergoing PCI by any stent platform in order to isolate the costs and complications associated with invasive versus noninvasive diagnostic strategies. It is possible that angina rates following PCI are different for bare metal versus drug eluting stents, and this study did not address these potential differences. Further, recent multicenter trial data suggest a lower rate of angina after PCI with BVS and thus the present analysis may have underestimated the efficacy of CCTA for evaluation of suspected ISR in BVS patients [29] . Each of the aforementioned study findings has important clinical implications. Given that multiple non-invasive tests are available to the physician as well as the reluctance of many patients to undergo repeat invasive diagnostic procedures, safe and economically sound non-invasive pathways that provide high diagnostic accuracy may support the need for standardized non-invasive clinical algorithms for patients with suspected ISR after PCI. These findings have important consequences, and may inform the design of future PCI trials that aim to reduce the economic burden of ISR evaluation to the healthcare system. This study is not without limitations. While all model inputs were obtained from contemporary prospective multicenter studies, they are nevertheless prone to potential publication biases that can affect all decision analytic models; future validation studies should be performed. Further, while we tested 3 distinct strategies that compared an invasive reference ''ground truth'' to non-invasive imaging by physiologic and anatomic methods, we did not assess the totality of available non-invasive methods including stress echocardiography, exercise treadmill testing, cardiac magnetic resonance imaging and positron emission tomography. For this analysis, we focused on CCTA and MPI as exemplars of the most commonly utilized anatomic and physiologic non-invasive imaging tests, respectively, for suspected ISR. Construction of a model incorporating all other available modalities is possible but will tender more information at the expense of precision and accuracy. Finally, while we examined the clinical outcomes related to test complications, we did not examine clinical outcomes related to incident myocardial infarction or cardiac-related death due to stent thrombosis. Because stent thrombosis rates are unknown for BVS, inclusion of this rare event (*0.1 % for BMS), would discriminatorily skew results in a favorable fashion towards any given diagnostic modality more effective at evaluation of BMS. Instead, this study sought to examine the economic effects of different testing strategies for ISR evaluation. Ongoing multicenter trials may help elucidate the potential differences in stent type and how these differences may have a direct effect on the cost efficiency of diagnostic testing for suspected ISR (NCT02173379).
Conclusion
On the basis of different diagnostic pathways, patients with suspected ISR incur lower costs and rates of complications when evaluated by a non-invasive versus invasive strategy.
While CCTA results in overall lower costs than MPI, CCTA strategy-based costs are dependent upon stent size and type.
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